ANI Pharmaceuticals Inc. (ANIP), a biopharmaceutical company, announced on Monday the launch of carbamazepine extended-release capsules, a generic version of the anticonvulsant Carbatrol.
Carbatrol has been approved by the U.S. Food and Drug Administration (FDA) for preventing seizures and in treating nerve pain associated with trigeminal neuralgia or diabetic neuropathy.
The U.S. annual sales for carbamazepine extended-release capsules were $65 million as of February 2026.
Previously, on April 8, 2026, the company reported FDA approval of the abbreviated new drug application (ANDA) for isosorbide mononitrate tablet USP. The drug is a generic version of Monoket, a vasodilator that widens blood vessels and prevents angina attacks.
ANIP closed Monday at $78.31, down 0.06%.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.